# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

### **SCHEDULE 13D**

(Rule 13d-101)

Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a)

Under the Securities Exchange Act of 1934 (Amendment No. 9)

## Solid Biosciences Inc.

(Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

> 83422E 105 (CUSIP Number)

Bain Capital Life Sciences Investors, LLC 200 Clarendon Street Boston, MA 02116 617-516-2000

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 $\label{eq:June 7, 2024} June \ 7, 2024 \\ \text{(Date of Event Which Requires Filing of This Statement)}$ 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing the schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. $\Box$				
<b>Note</b> . Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.				
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchang Act of 1934, as amended ("Act"), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).				

1	1 Names of reporting persons			
	DOLG OD Y			
			nvestco, LP	
2			ppropriate box if a member of a group	
	(a)			
3	SEC u	se onl		
,	SEC u	SC OIII	y .	
4	Source	e of fu	ands	
	WC			
5	Check	if dis	closure of legal proceedings is required pursuant to Item 2(d) or 2(e)	
6	Citize	nship	or place of organization	
	Delaw	are		
	Delavi	7	Sole voting power	
		,	Sold forming porter	
	mber of		0 shares of Common Stock	
	shares	8	Shared voting power	
	eficially aned by			
	each		528,660 shares of Common Stock	
reporting		9	Sole dispositive power	
person				
with:		10	0 shares of Common Stock	
		10	Shared dispositive power	
			528,660 shares of Common Stock	
11	Aggre	gate a	mount beneficially owned by each reporting person	
			res of Common Stock	
12	Check if the aggregate amount in Row (11) excludes certain shares			
10				
13	Percer	t of c	lass represented by amount in Row (11)	
	1.4%			
14				
'	1. Type of tepotaing potion			
	PN			
	<u> </u>			

1	Names of reporting persons			
	Bain Capital Life Sciences Fund II, L.P.			
2			ppropriate box if a member of a group	
	(a) 🗆		b)	
	, ,			
3	SEC u	se onl	V	
4	Source	e of fu	inds	
	SC			
5	Check	if dis	closure of legal proceedings is required pursuant to Item 2(d) or 2(e)	
6	Citize	nship	or place of organization	
	Caym	an Isl		
		7	Sole voting power	
	1 0			
	mber of		0 shares of Common Stock	
	shares eficially	8	Shared voting power	
	ned by			
	each		267,257 shares of Common Stock	
	porting	9	Sole dispositive power	
	erson			
_	with:		0 shares of Common Stock	
		10	Shared dispositive power	
			267,257 shares of Common Stock	
11	Aggre	gate a	mount beneficially owned by each reporting person	
	245.0			
- 10			res of Common Stock	
12	2 Check if the aggregate amount in Row (11) excludes certain shares			
12				
13	Percent of class represented by amount in Row (11)			
	0.79/			
14	0.7%			
14	14 Type of reporting person			
	PN			
	111			

1	1 Names of reporting persons			
	BCLS II Investco, LP			
2	Check	the a	ppropriate box if a member of a group	
	(a) 🗆		b)	
3	SEC u	se onl	V	
4	Source	e of fu	nds	
	WC, S			
5	Check	if dis	closure of legal proceedings is required pursuant to Item 2(d) or 2(e)	
6	Citize	nship	or place of organization	
	Delaw			
		7	Sole voting power	
NI	mber of			
	shares		0 shares of Common Stock	
	eficially	8	Shared voting power	
	ned by			
	each		2,301,955 shares of Common Stock	
re	porting	9	Sole dispositive power	
p	erson			
with:		1.0	0 shares of Common Stock	
		10	Shared dispositive power	
2301.055 1		2,301,955 shares of Common Stock		
11	Aggra	roto o	mount beneficially owned by each reporting person	
11	Aggre	gate a	mount beneficiarily owned by each reporting person	
	2 301	955 el	nares of Common Stock	
12			aggregate amount in Row (11) excludes certain shares	
12	CHECK	II tiic	aggregate amount in Now (11) excludes certain shares	
13				
	1 Total of the transfer of minorial in ten (11)			
	6.0%			
14				
		-		
	PN			

1	Names of reporting persons			
	BCIP Life Sciences Associates, LP			
2	Check	the a	ppropriate box if a member of a group	
	(a) 🗆	(	$\stackrel{\circ}{\Box}$	
3	SEC u	se onl	ly	
4	Source	e of fu	ands .	
	SC			
5	Check	if dis	closure of legal proceedings is required pursuant to Item 2(d) or 2(e)	
	_			
6	Citize	nship	or place of organization	
	ъ.			
	Delaw			
		7	Sole voting power	
Nu	mber of			
	hares		0 shares of Common Stock	
	eficially	8	Shared voting power	
	ned by		22 550 -h of Common Stock	
	each	9	32,550 shares of Common Stock	
	porting	9	Sole dispositive power	
_	person		0 shares of Common Stock	
,	with:	10	Shared dispositive power	
		10	Shared dispositive power	
			32,550 shares of Common Stock	
11	Aggre	rate a	mount beneficially owned by each reporting person	
11	nggi C	5ate a	mount otheretary owned by each reporting person	
	32,550	shar	es of Common Stock	
12				
12	2 Check if the approprie amount in Now (11) excludes contain shares			
13				
	Less than 0.1%			
14	Type o	f repo	orting person	
	DP.			
	PN			

1	1 Names of reporting persons			
	BCLS II Equity Opportunities, LP			
2	Check (a) □		ppropriate box if a member of a group b) □	
3	SEC u	se onl	у	
4	4 Source of funds			
	WC			
5	Check	if dis	closure of legal proceedings is required pursuant to Item 2(d) or 2(e)	
6	Citize	nship	or place of organization	
	Delaw			
		7	Sole voting power	
	mber of		0 shares of Common Stock	
	shares eficially	8	Shared voting power	
owned by each			904,160 shares of Common Stock	
re	porting	9	Sole dispositive power	
person with:			0 shares of Common Stock	
WILII.		10	Shared dispositive power	
			904,160 shares of Common Stock	
11	Aggre	gate a	mount beneficially owned by each reporting person	
	904.16	60 sha	res of Common Stock	
12				
13	Percent of class represented by amount in Row (11)			
	2.4%			
14	Type o	f repo	orting person	
	PN			
		•		

This Amendment No. 9 to Schedule 13D relates to the Common Stock of Solid Biosciences Inc. and amends the initial statement on Schedule 13D filed by BCLS SB Investco, LP on February 1, 2018, as amended by Amendment No. 1 filed on July 30, 2019, Amendment No. 2 filed on December 11, 2020, Amendment No. 3 filed on March 25, 2021, Amendment No. 4 filed on August 18, 2022, Amendment No. 5 filed on October 3, 2022, Amendment No. 6 filed on December 5, 2022, Amendment No. 7 filed on January 10, 2024 and Amendment No. 8 filed on January 12, 2024 (the "Initial Statement" and, as further amended by this Amendment No. 9, the "Schedule 13D"). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Initial Statement.

#### Item 4. Purpose of Transaction

Item 4 of the Initial Statement is hereby amended and supplemented to add the following:

On June 7, 2024, Adam Koppel, a Partner of BCLSI, tendered his resignation from the Issuer's Board of Directors, effective as of June 11, 2024.

#### **SIGNATURES**

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: June 11, 2024

#### **BCLS SB Investco, LP**

By: Bain Capital Life Sciences Partners, LP, its general partner

By: Bain Capital Life Sciences Investors, LLC, its general partner

By: /s/ Adam Koppel
Name: Adam Koppel

Title: Partner

#### Bain Capital Life Sciences Fund II, L.P.

By: Bain Capital Life Sciences Investors II, LLC, its general partner

By: Bain Capital Life Sciences Investors, LLC, its manager

By: /s/ Adam Koppel
Name: Adam Koppel

Title: Partner

#### BCLS II Investco, LP

By: BCLS II Investco (GP), LLC, its general partner

By: Bain Capital Life Sciences Fund II, L.P., its managing member

By: Bain Capital Life Sciences Investors II, LLC, its general partner

By: Bain Capital Life Sciences Investors, LLC, its manager

By: /s/ Adam Koppel
Name: Adam Koppel

Title: Partner

#### **BCIP Life Sciences Associates, LP**

By: Boylston Coinvestors, LLC, its general partner

By: /s/ Adam Koppel
Name: Adam Koppel
Title: Authorized Signatory

#### **BCLS II Equity Opportunities, LP**

By: BCLS II Equity Opportunities GP, LLC, its general partner

By: Bain Capital Life Sciences Fund II, L.P., its manager

By: Bain Capital Life Sciences Investors II, LLC, its general partner

By: Bain Capital Life Sciences Investors, LLC, its manager

By: /s/ Adam Koppel
Name: Adam Koppel

Title: Partner